Page last updated: 2024-10-28

fasudil and Cytokine Release Syndrome

fasudil has been researched along with Cytokine Release Syndrome in 1 studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Xia, L1
Yuan, LZ1
Hu, YH1
Liu, JY1
Hu, GS1
Qi, RY1
Zhang, TY1
Xiong, HL1
Zheng, ZZ1
Lin, HW1
Zhang, JM1
Yu, C1
Zhou, M1
Ma, J1
Cheng, T1
Chen, RR1
Guan, Y1
Xia, NS1
Liu, W1

Other Studies

1 other study available for fasudil and Cytokine Release Syndrome

ArticleYear
A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
    Cellular & molecular immunology, 2023, Volume: 20, Issue:4

    Topics: Caspofungin; COVID-19; Cytokine Release Syndrome; Cytokines; Felodipine; Humans; Imatinib Mesylate;

2023